Stanford University
Showing 20,701-20,750 of 36,179 Results
-
Rishi Mediratta
Clinical Associate Professor, Pediatrics
Current Research and Scholarly InterestsI have developed a new promising neonatal mortality prediction score at the University of Gondar Neonatal Intensive Care Unit (NICU) in Gondar, Ethiopia. The score predicts approximately 84% of neonatal deaths in the NICU using clinical variables. I have a dataset over 800 NICU admissions in Gondar. I am recruiting scholars who are interested in conducting clinical and epidemiological research to validate, refine, and implement the mortality score to reduce neonatal mortality in Ethiopia.
-
Sangeeta Mediratta
PWR Lecturer
BioSangeeta Mediratta teaches classes on rhetoric and writing, literature and film. Her PWR classes currently focus on maps, borders, networks, objects, and objectification. She loves learning about and helping her students develop their research interests and projects and takes great joy in fostering strong class communities centered around writing and research.
She completed her Ph.D. from University of California, San Diego in English Literature. Her dissertation :Bazaars, Cannibals, and Sepoys: Sensationalism and Transnational Cultures of Empire" studied at the ways texts, objects, and spectacles in the U.S. and Britain drew upon imperial stories and objects to critique contemporary social formations. She has also written on world cinema, popular culture, disability studies, as well as gender and race studies.
Her current research focuses on the materiality of writing and on how students use culture as a way to build campus communities. She is also interested in empathy as a mode of living, connecting, writing, and being. -
Natalia Medvedeva
Clinical Assistant Professor, Medicine - Infectious Diseases
BioDr Natalia Medvedeva specializes in the treatment of infectious diseases. She has a special interest in antimicrobial stewardship and medical education.
-
Lúcia Mees
MBA, expected graduation 2026
Course Asst-Graduate-Hourly, SeruBioElectrical and Computer Engineer & Entrepreneur with focal interest in Artificial Intelligence and IoT. Currently working in the development of next-gen smart cities in Brazil, the world's 2nd most advanced country in digital government.
My work focuses on innovation and digital transformation strategy, developing short, medium and long-term roadmaps for technology solutions propelling public administration over hundreds of cities in the country. Under my leadership at IPM, our SaaS platform has been awarded as the best solution for smart cities in Brazil, as one of the 2 most innovative software companies in Southern Brazil, and as the 5th best HR team in the country. -
Eric Meffre
Professor of Medicine (Immunology and Rheumatology)
BioDr. Meffre obtained his PhD in Immunology from the Université d’Aix-Marseille in France before he moved to the USA as a postdoc fellow in the laboratory of Dr. Michel Nussenzweig at The Rockefeller University in New York City. He became an assistant professor at Cornell University in 2003 before being recruited at Yale University as associate professor in 2009. He was tenured at Yale in 2014 before he joined the Department of Medicine/Division of Immunology and Rheumatology at Stanford University as a tenured full professor in 2022.
Dr. Meffre’s work focuses on the etiology of autoimmune syndromes and the roles played by B cells in these diseases. His group characterized the abnormal selection of developing autoreactive B cells in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS) and Sjögren’s syndrome, resulting in large numbers of autoreactive naïve B cells accumulating in the patient’s blood. Hence, these autoreactive B cells may present self-antigens to T cells and initiate autoimmune diseases. These early B cell tolerance defects are likely primary to these autoimmune diseases and may result from genetic factors such as the 1858T PTPN22 allele that segregates with RA, SLE and T1D and correlate with an impaired removal of developing autoreactive B cells.
His research goals also consist in characterizing the molecules and pathways involved in the establishment of B cell tolerance and the removal of developing autoreactive B cells generated by random V(D)J recombination through the investigation of rare patients with primary immunodeficiency (PID) enrolled through an international network. Alteration of B cell receptor (BCR) or Toll-like receptor (TLR) signaling in PID patients results in a defective central B cell tolerance and a failure to counterselect developing autoreactive B cells in the bone marrow. In contrast, functional and suppressive regulatory T cells play a key role in preventing the accumulation of autoreactive clones in the mature naïve B cell compartment. The recent development of humanized mouse models recapitulating early B cell tolerance checkpoints and their defects in autoimmune settings allow further in-depth investigation of tolerance mechanisms and the development of novel approaches to restore defective central and peripheral B cell tolerance checkpoints and thwart autoimmunity. -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily and former Chief Medical Officer of Google Life Sciences. She is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy. She is a Senior Advisor at SandboxAQ and the Chair of the Investment Committee of the American Heart Association’s GRFW Venture Fund.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies and new medical technologies. She directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association and the American College of Cardiology. -
Uchechukwu Megwalu, MD, MPH
Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsOutcomes Research
Health Disparities
Comparative Effectiveness Research
Health Literacy
Head and Neck Cancer Epidemiology
SEER database analysis -
Thulaj Dattatraya Meharwade
Postdoctoral Scholar, Cardiovascular Institute
BioDr. Thulaj Meharwade is a postdoctoral fellow at the Stanford Cardiovascular Institute with research interests in Inflammaging, disease modeling, cellular heterogeneity and drug discovery. Dr. Meharwade received his PhD in Biochemistry from the University of Montreal, after conducting thesis work on signalling and transcriptional mechanisms regulating cell fate heterogeneity and totipotent stem cells.
-
Rania Zuri
Undergraduate, Vice Provost for Undergraduate Education
BioRania Zuri is the founder and CEO of The LiTEArary Society, the world’s largest youth-led nonprofit organization working to end book deserts for disadvantaged preschool children. To date, The LiTEArary Society has donated more than $1 million worth of brand new books to over 91,000 disadvantaged preschool children in all 50 states. The LiTEArary Society has partnerships and has received funding from Scholastic, Inc., Barnes & Noble, L'Oréal, Hershey’s, Pilot Pens, and Starbucks.
For her work in early childhood literacy, she has been featured on Good Morning America, Forbes, NBC Nightly News with Lester Holt, The Today Show, The Kelly Clarkson Show (x2), CBS Evening News, NPR, Fox News, Teen Vogue, The Washington Post, NowThis, The Hill, People Magazine, and more.
She was named by Forbes as one of "Six Teens Making the World a Better Place” in 2022 and made the Forbes 30 under 30 list in 2024 as the youngest CEO on the entire list. In 2023, Rania received The Diana Award, one of the most prestigious international accolades a young person (ages 8 to 25) can receive for social or humanitarian work and was one of only 3 recipients out of the 189 global recipients to be introduced by Prince Harry. In 2023, Rania was honored at the White House by the First Lady of the United States as a "Girl Leading Change" in celebration of International Day of the Girl. Most recently, Rania was honored by L'Oréal Paris as a L’Oréal Woman of Worth, L'Oréal's signature philanthropic initiative which honors 10 female leaders each year.
Rania has given a TEDx Talk on book deserts with over 43,000 views on TED.com and Youtube and was the keynote speaker at the annual WV Head Start Conference. She has written op-eds for Teen Vogue and NBC News Online on education as well. She serves as an ambassador for many organizations and corporations, including the United Nations Association (as a UNA-USA Global Goals Ambassador for Sustainable Development Goal #4).
She is the youngest author of a US Senate Resolution in U.S. history and has written a children’s picture book series (sold in-store at select Barnes & Noble stores) where 100% of the profits go to the purchase of brand-new Scholastic books for preschool children in Head Start programs.
Rania is a Coca-Cola Scholar, a U.S. Presidential Scholar, a Cameron Impact Scholar, a Taco Bell Live Mas Scholar, winner of the Gloria Barron Prize for Young Heroes, and has received 3 US Congressional Commendations as well as the George H.W. Bush Point of Light Award. -
Apurva Mehta
Senior Scientist, SLAC National Accelerator Laboratory
BioI am a materials scientist with three decades of experience unraveling the molecular-scale processes that govern the functionality, aging, and failure of complex materials and devices. Over this time, advanced characterization methods have undergone a revolutionary transformation, driven by the emergence of brighter sources—from synchrotrons and X-ray free-electron lasers to MeV accelerator-based electron sources—paired with faster and larger-area detectors. While the depth and precision of measurements have vastly improved, the explosion of raw data now poses a significant challenge, making it increasingly difficult to extract meaningful insights them.
Recognizing this growing challenge, I have devoted the last decade to harnessing the power of emerging machine learning and artificial intelligence techniques to find breakthroughs. My focus has been on not only accelerating the extraction of knowledge from intricate, multi-dimensional, and often noisy measurements but also on making data collection smarter. By integrating these cutting-edge technologies, I aim to transform how we approach material science and deepen our understanding of material behavior and device performance. -
Arnav Mehta, MD, PhD
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioDr. Mehta is a board-certified, fellowship-trained medical oncologist at the Stanford Medicine Cancer Center. He is also an adjunct clinical assistant professor in the gastrointestinal (GI) oncology group of the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Mehta specializes in gastrointestinal cancer, with a particular focus on pancreatic and gastric cancers. He also treats colorectal cancers. His treatment specialties include immunotherapy — helping a patient’s immune system fight cancer — and targeted therapies, which send cancer-fighting drugs to specific cancer cell molecules.
His research interests include understanding why GI cancers resist treatments and identifying new ways to treat these tumors. In particular, he is interested in GI tumor immunology, which focuses on directing a person’s immune system to help destroy cancer cells. He also has a special interest in tumor plasticity, which represents the ability of a tumor cell to evolve and develop resistance to therapies.
Dr. Mehta has earned research awards and grants from organizations including the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and the National Institutes of Health.
Dr. Mehta has published in many peer-reviewed journals, including Nature, Nature Genetics, Nature Immunology, Nature Medicine, Nature Cancer, Cancer Discovery and Immunity. He has written book chapters on subjects including esophageal and gastric cancer. He has also presented his research on topics including tumor immunology and pancreatic cancer at dozens of symposia and meetings around the country.
Dr. Mehta is a member of the AACR and ASCO. -
Krish Mehta
Affiliate, Graduate School of Business - Center for Entrepreneurial Studies
BioPassionate about cleantech / climate entrepreneurship. Previously, manager for Model 3 program at Tesla, and Engagement manager at McKinsey's Sustainability practice.
-
Niraj Mehta
MBA, expected graduation 2027
Current Research and Scholarly InterestsPlants provide some of the most important drugs in current clinical use. It can be challenging to chemically synthesize these drugs or sustainably source them from producer plants. These issues could be alleviated if their biosynthetic genes are engineered into heterologous organisms for large-scale production. I am interested in a) understanding how plants produce these valuable drugs and b) engineering the sustainable production of these drugs into other plants for large-scale production.
